EGFR activating mutation plus exon 20 co-mutation at baseline: Which TKI should we select for frontline treatment?

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session Guiding the best targeted treatment
Topics Lung and other Thoracic Tumours
Personalised Medicine
Presenter Egbert Smit
Authors E.F. Smit
  • Pulmonary Diseases, The Netherlands Cancer Institute, 1060NN - Amsterdam/NL